Patient characteristics of the TMB subgroups
| Clinical characteristics | All (N=2165) | TMB <10 (N=1307) | TMB 10–19 (N=622) | TMB ≥20 (N=236) | P value |
| Age at advanced Dx | 70.0 (63.0; 76.0) | 71.0 (63.0; 76.0) | 69.0 (63.0; 76.0) | 67.0 (58.0; 73.0) | <0.001 |
| Gender | 0.188 | ||||
| Female | 1035 (47.8%) | 615 (47.1%) | 315 (50.6%) | 105 (44.5%) | |
| Male | 1130 (52.2%) | 692 (52.9%) | 307 (49.4%) | 131 (55.5%) | |
| Self-reported race | 0.559 | ||||
| White | 1479 (68.3%) | 909 (69.5%) | 418 (67.2%) | 152 (64.4%) | |
| Black or African American | 171 (7.90%) | 98 (7.50%) | 52 (8.36%) | 21 (8.90%) | |
| Others | 515 (23.8%) | 300 (23.0%) | 152 (24.4%) | 63 (26.9%) | |
| Practice type | 0.971 | ||||
| Academic | 155 (7.16%) | 94 (7.19%) | 45 (7.23%) | 16 (6.78%) | |
| Community | 2010 (92.8%) | 1213 (92.8%) | 577 (92.8%) | 220 (93.2%) | |
| Histology | <0.001 | ||||
| Non-squamous cell carcinoma | 1577 (72.8%) | 965 (73.8%) | 429 (69.0%) | 183 (77.5%) | |
| NSCLC histology NOS | 93 (4.30%) | 50 (3.83%) | 25 (4.02%) | 18 (7.63%) | |
| Squamous cell carcinoma | 495 (22.9%) | 292 (22.3%) | 168 (27.0%) | 35 (14.8%) | |
| Stage at Dx | 0.326 | ||||
| I | 214 (9.88%) | 122 (9.33%) | 62 (9.97%) | 30 (12.7%) | |
| II | 145 (6.70%) | 92 (7.04%) | 40 (6.43%) | 13 (5.51%) | |
| III | 326 (15.1%) | 180 (13.8%) | 110 (17.7%) | 36 (15.3%) | |
| IV | 1448 (66.9%) | 895 (68.5%) | 399 (64.1%) | 154 (65.3%) | |
| Unknown | 32 (1.48%) | 18 (1.38%) | 11 (1.77%) | 3 (1.27%) | |
| History of smoking | <0.001 | ||||
| History of smoking | 2032 (93.9%) | 1187 (90.8%) | 616 (99.0%) | 229 (97.0%) | <0.001 |
| No history of smoking | 133 (6.14%) | 120 (9.18%) | 6 (0.96%) | 7 (2.97%) | |
| ECOG | 0.028 | ||||
| 0~1 | 1486 (68.6%) | 924 (70.7%) | 401 (64.5%) | 161 (68.2%) | |
| 2+ | 484 (22.4%) | 266 (20.4%) | 167 (26.8%) | 51 (21.6%) | |
| Unknown | 195 (9.01%) | 117 (8.95%) | 54 (8.68%) | 24 (10.2%) | |
| Therapy | 0.001 | ||||
| ICPI | 846 (39.1%) | 470 (36.0%) | 265 (42.6%) | 111 (47.0%) | |
| ChemoICPI | 1319 (60.9%) | 837 (64.0%) | 357 (57.4%) | 125 (53.0%) | |
| PD-L1 (TS) | 0.676 | ||||
| <1% | 680 (31.4%) | 416 (31.8%) | 192 (30.9%) | 72 (30.5%) | |
| 1–49% | 650 (30.0%) | 399 (30.5%) | 176 (28.3%) | 75 (31.8%) | |
| ≥50% | 835 (38.6%) | 492 (37.6%) | 254 (40.8%) | 89 (37.7%) |
chemoICPI, ICPI with chemotherapy; Dx, diangosis; ECOG, Eastern Cooperative Oncology Group Performance Status Scale; ICPI, immune checkpoint inhibitors; NOS, not otherwise specified; NSCLC, non-small cell lung cancer; PD-L1, programmed death ligand-1; TMB, tumor mutational burden; TS, tumor staining.